Kalypsys is focused on three therapeutic areas that target some of the world's most widespread diseases including cardiovascular/metabolic diseases, pain/inflammation and oncology. We are working diligently to discover and develop innovative medicines that will help care for and cure patients suffering from these conditions.
Metabolic syndrome affects an estimated 47 million Americans. The condition is associated with a significant increased risk of cardiovascular heart disease. Our lead program, KD3010, is a PPARδ selective agonist that is currently being evaluated for its ability to address the underlying causes of metabolic syndrome. More >
Pain is the most common reason people seek medical attention. We are developing innovative drugs to treat multiple pain states. Our lead program, KD7040, is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. More >
Cancer is the second leading cause of death in the U.S., claiming more than 570,000 lives in 2005. Our lead program, KD5170, is a histone deacetylase (HDAC) inhibitor for treatment of hematological and solid tumors. More >